Vitamin D3 for Life

Live Enlightened

Article

Vitamin D supplementation increased pathological complete response during neoadjuvant chemotherapy in breast cancer (2025 RCT): Study Summary

Previous related pageVitamin D and Mitochondrial FunctionNext related pageVitamin D, Apoptotic Signalling and Human Tissue Markers: Full Evidence Review
Study at a glance

Did vitamin D3 change the response to chemotherapy before breast-cancer surgery?

Researchers tested vitamin D3 during chemotherapy given before breast-cancer surgery. Eighty women aged 45 or older were assigned by chance to vitamin D3 or an inactive treatment called a placebo. The vitamin D3 dose was 2,000 international units (IU) each day for six months.

What did the breast tissue results show after treatment?

Seventy-five women completed chemotherapy and had surgery. In 43% of women given vitamin D3 and 24% given placebo, no remaining invasive cancer was found in the tissue examined. This is called a pathological complete response. Blood levels of the measured form of vitamin D, called 25-hydroxyvitamin D, also rose with vitamin D3.

Does this prove that vitamin D treats breast cancer or improves survival?

The finding concerns response to chemotherapy in this trial. It does not establish that vitamin D alone treats breast cancer. The reported outcome is not the same as proving a longer-term survival benefit.

Read the full article below ↓

Study overview

Omodei M S et al. (2025) tested whether vitamin D3 supplementation could improve pathological complete response rates in women receiving neoadjuvant chemotherapy for breast cancer. This randomized clinical trial was published in Nutrition and Cancer.

What this study shows

In women with breast cancer undergoing neoadjuvant chemotherapy, daily vitamin D3 (2,000 IU) for 6 months increased serum 25(OH)D levels and was associated with a higher pathological complete response rate than placebo (43% vs 24%). In adjusted analysis reported by the authors, achieving 25(OH)D levels at or above 20 ng/mL was associated with higher odds of pathological complete response.

Key details

  • Design: randomized clinical trial
  • Participants: 80 women aged 45+ eligible for neoadjuvant chemotherapy; 75 completed treatment and underwent surgery
  • Intervention: vitamin D3 (cholecalciferol) 2,000 IU/day for 6 months vs placebo
  • Outcomes measured: pathological complete response (primary), serum 25(OH)D
  • Main finding direction: higher pCR rate with vitamin D supplementation

Primary source

Vitamin D Supplementation Improves Pathological Complete Response in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Randomized Clinical Trial (PubMed)

Related reading

Original sources

Source

Vitamin D Supplementation Improves Pathological Complete Response in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Randomized Clinical Trial (PubMed)

Vitamin D Supplementation Improves Pathological Complete Response in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Randomized Clinical Trial (PubMed).

Publication details

Vitamin D Supplementation Improves Pathological Complete Response in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Randomized Clinical Trial (PubMed)

Read more →